OTC Markets OTCPK - Delayed Quote USD

Zealand Pharma A/S (ZLDPF)

34.57 +1.49 (+4.51%)

At close: November 2 at 4:00:00 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

GlobeNewswire 15d ago

ZEAL.CO
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

GlobeNewswire 21d ago

GENB

ZEAL.CO
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

GlobeNewswire 21d ago

GENB

ZEAL.CO
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

GlobeNewswire 27d ago

ZEAL.CO
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

GlobeNewswire 29d ago

ZEAL.CO

DANSKE.CO
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts

GlobeNewswire 1mo ago

ZEAL.CO
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

GlobeNewswire 1mo ago

ZEAL.CO
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

GlobeNewswire 1mo ago

ZEAL.CO
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

GlobeNewswire 1mo ago

ZEAL.CO
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

GlobeNewswire 1mo ago

ZEAL.CO
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

GlobeNewswire 1mo ago

ZEAL.CO
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

GlobeNewswire 1mo ago

ZEAL.CO

Performance Overview

Return	ZLDPF	OMX Copenhagen 25 Index (^OMXC25)
YTD	-51.71%	--
1-Year	-53.83%	+18.02%
3-Year	-20.99%	+21.75%

U.S. markets closed

Zealand Pharma A/S (ZLDPF)

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)